Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. The 2021 estimates are for Iterum Therapeutics plc earnings to increase by 69.5%, but the outlook for the next 5-year period is at 0% per year. Press Release reported on 02/03/21 that Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million Iterum Therapeutics (NASDAQ:ITRM) inks agreements with institutional investors for the direct sale of 3,372,686 ordinary shares at $1.4825/share. How has Iterum Therapeutics's share price performed over time and what events caused price changes? Iterum Therapeutics (NASDAQ:ITRM) is in the news Thursday following news of massive stakes in the company pushing ITRM stock higher. Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem 06.01.21 Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Thinking about buying stock in AMC Entertainment, Zynga, Iterum Therapeutics, Inuvo, or Plug Power? When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the … Let’s break this Iterum Therapeutics news down below. When autocomplete results are available use up and down arrows to review and enter to select. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Iterum Therapeutics News: This is the News-site for the company Iterum Therapeutics on Markets Insider The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Latest Share Price and Events. Iterum Therapeutics plc (NASDAQ:ITRM) major shareholder Alexander J. Denner sold 10,000,000 shares of the business’s stock in a transaction on Thursday, February 11th. $38.05. Likewise, he now holds 10 million shares of ITRM stock and an 18.9% stake in the company. Iterum Therapeutics plc Irish Registration No. Daisy Galbraith-December 22, 2020 0. The company report on March 6, 2021 that Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021. Next up is RA Capital Management managing partner Peter Kolchinsky, who also bought 10 million shares of the stock. Find the latest news headlines from Iterum Therapeutics plc Ordinary Share (ITRM) at Nasdaq.com. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Iterum Therapeutics (ITRM) stock is taking off on Tuesday with heavy trading even without any news coming from the company. Get the hottest stocks to trade every day before the market opens 100% free. Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections. Type a symbol or company name. ITRM stock was up 41.5% as of Thursday morning. 12, 2021 7:03 AM ET Iterum Therapeutics plc (ITRM) By: Jignesh Mehta, SA News Editor 3 Comments Iterum Therapeutics (NASDAQ: ITRM ) : Q4 Non-GAAP EPS of … Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the … Do Not Sell My Personal Information (CA Residents Only). Nasdaq Log In. Best deals to access real time data! Cancel. The good news is that Iterum Therapeutics will collect gross proceeds of approximately $35 million, before placement agent’s fees and other offering expenses are deducted. NASDAQ 0.00%. That has it holding a 16.5% stake in the company. The company’s stock price has collected -5.67% of loss in the last five trading sessions. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. Iterum Therapeutics plc [NASDAQ: ITRM] surged by $0.07 during the normal trading session on Tuesday and reaching a high of $1.50 during the day while it closed the day at $1.44. Starting off, RA Capital Management, which is based out of Delaware, now holds 10 million shares of ITRM stock. Monthly Subscription. DUBLIN, Ireland and CHICAGO, June 29, 2020 (GLOBE NEWSWIRE) -- Iterum … What Will the Stock Market Do Today? Trending now. At the very opening of the session, the stock price was $1.41 and reached a high price of $1.46, prior to closing the session it reached the value of $1.41. Finally, we have RA Capital Healthcare Fund picking up 8,486,000 shares of Iterum Therapeutics’ stock. Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the … The company’s stock price has collected -15.57% of loss in the last five trading sessions. Iterum Therapeutics plc (NASDAQ:ITRM) went down by -6.29% from its latest closing price compared to the recent 1-year high of $6.02. 7 Penny Stocks That Might Be Headed to $0, Churchill Capital IV Stock Could Still Rally, 7 Retail Stocks That Are in Danger of Becoming the Next Sears, 7 Value Stocks That Will Reward Investors Who Have Some Patience, Facing Pressure, Nio Stock Could Decline Further. The company’s stock price has collected 57.69% of gains in the last five trading sessions. A filing with the U.S. Securities and Exchange Commission (SEC) reveals that several members connected to RA Capital Management have taken a stake in the company. Iterum Therapeutics plc Ordinary Share (ITRM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Our Company Prior to joining Iterum, Tom served as Director of API Development at Ipsen from 2004 and was a member of their CMC and Dublin manufacturing site leadership teams. That’s quite the jump from the company’s daily average trading volume of 6.65 million shares. for only. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Recently in News on February 19, 2021, Iterum Therapeutics to Present in Upcoming Investor Conferences. This gives it … These symbols will be available throughout the site during your session. CHART Trader. Iterum Therapeutics News: Why ITRM Stock Is Rocketing Higher Today, 4 Big Reasons Hard-Hit Nio Is Rebounding Today >>> READ MORE, Investors Are Watching for Spotify’s Catalyst, Louis Navellier and the InvestorPlace Research Staff, Why $30 May Be the Floor for Plug Power Stock. Post-Market 0.03 (2.13%) Get Iterum Therapeutics PLC (ITRM:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Iterum Therapeutics plc (NASDAQ:ITRM) concluded the trading at $1.41 on Friday, Mar 26, with a fall of -0.61% from its closing price on previous day. Iterum Therapeutics plc [NASDAQ: ITRM] gained 6.40% or 0.08 points to close at $1.33 with a heavy trading volume of 17087844 shares. Iterum Therapeutics plc (NASDAQ:ITRM) went down by -0.70% from its latest closing price compared to the recent 1-year high of $6.02. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0%. Stable Share Price: ITRM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 24% a week. Let’s break this Iterum Therapeutics news down below. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. Business Here’s How Your Trade Iterum Therapeutics plc (ITRM) Aggressively Right Now. View the latest Iterum Therapeutics PLC (ITRM) stock price, news, historical charts, analyst ratings and financial information from WSJ. This has resulted in these new investors owning more than 73% of ITRM stock. $33.03. Real-time trade and investing ideas on Iterum Therapeutics ITRM from the largest community of traders and investors. Iterum Therapeutics plc [ITRM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 50.00. Iterum Therapeutics plc (NASDAQ:ITRM) went up by 6.40% from its latest closing price compared to the recent 1-year high of $6.02. The company’s stock price has collected -20.77% of loss in the last five trading sessions. How has Iterum Therapeutics's share price performed over time and what events caused price changes? Gross … Copy and paste multiple symbols separated by spaces. DOW 0.00%. Read current news for ITRM (XNAS). The company’s stock... Read more. 3 Big Stories to Watch. Shares of ITRM stock have seen massive amounts of trading in the early hours of today. Get the hottest stocks to trade every day before the market opens 100% free. Iterum Therapeutics plc (ITRM) is priced at $1.36 after the most recent trading session. Top institutional investors include Pivotal bioVenture Partners Investment Advisor LLC (1.93%), Renaissance Technologies LLC (1.49%), Focused Wealth Management Inc (0.15%), Grimes & Company Inc. (0.15%), Clear Street Markets LLC (0.05%) and Virtu Financial LLC (0.04%). Iterum Therapeutics stock has been on a bull run in the past few days - shares have risen in value from $1.3 on February 4th, to $2.73 at the time of writing - a gain of 110%. Get the hottest stocks to trade … With this latest performance, ITRM shares dropped by -31.49% in over the last four-week period, additionally plugging by 168.33% over the last 6 months – not to mention a drop of -16.15% in the past year of trading. Download as PDF . for only. Rooms Shows Rankings Earnings Calendar Shop. Iterum Therapeutics plc (ITRM) estimates and forecasts. 1125 N. Charles St, Baltimore, MD 21201. This gives it an 18.9% stake in Iterum Therapeutics. Click here now. Harcourt Street, Dublin. The company’s stock price has collected -15.57% of loss in the last five trading sessions. February 10, 2021 - 6:40 pm. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Press Release reported on 03/16/21 that Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors. Free real-time prices, trades, and chat. Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. The stock touched a low price of $1.32. Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens. Such a massive stake in a company shows that the investors have seen so much value in Iterum Therapeutics. Iterum Therapeutics' stock is owned by many different retail and institutional investors. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Iterum Therapeutics against related stocks people … Tom Loughman, Ph.D. joined Iterum Therapeutics in late 2016 as VP, CMC and Manufacturing. Iterum Therapeutics plc (NASDAQ:ITRM) went up by 6.03% from its latest closing price compared to the recent 1-year high of $6.02. View the real-time ITRM price chart on Robinhood and decide if you want to buy or sell commission-free. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. for only. Starting off, RA Capital Management, which is based out of Delaware, now holds 10 million shares of ITRM stock. Iterum Therapeutics Plc Stock News NASDAQ:ITRM. Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem. Mar. The company report on February 4, 2021 that Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million.. Get the hottest stocks to trade every day before the market opens 100% free. Iterum Therapeutics news and ITRM price. Now we move on to Rajeev Shah, another managing partner at RA Capital Management. Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced … As of this writing, more than 79 million shares have changed hands. Iterum Therapeutics plc (NASDAQ:ITRM) went up by 42.61% from its latest closing price compared to the recent 1-year high of $7.19. All rights reserved. Free trial. Create your Watchlist to save your favorite quotes on Nasdaq.com. As reported in Schedule 3G filing, RA Capital Management owns approximately 18.9% stake in the Irish company. Type a symbol or company name. Press Release reported on 02/19/21 that Iterum Therapeutics to Present in Upcoming Investor Conferences. Iterum Therapeutics Plc is a pharmaceutical company, which engages in the development and commercialization of sulopenem to …